AstraZeneca Gets CDSCO Panel Nod To study COPD Drug Tozorakimab
New Delhi: Pharmaceutical major AstraZeneca has got the green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase II clinical trial of the Chronic Obstructive Pulmonary Disease (COPD) drug Tozorakimab.
This came after the firm presented a study for acute viral infection respiratory failure (ARDS) except for COVID-19 and proposed conducting Phase II study vide protocol no: D9185C00001 version 1.0, 15-sep-2022 and local CSP Addendum IND-1: version 1.0, dated 14-Oct-2022 before the committee.
Tozorakimab (MEDI-3506) is under development for the treatment of diabetic kidney disease, Coronavirus disease (COVID-19), chronic bronchitis, asthma, acute respiratory failure, and chronic obstructive pulmonary disease (COPD). The drug candidate is administered through a subcutaneous or intravenous route in the form of a solution. It is a monoclonal antibody that acts by targeting the interleukin-33 (IL-33). The drug candidate is a new molecular entity. It was also under development for the treatment of atopic dermatitis
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.